L&K Bio Reports Q1 Operating Profit of 1.7 Billion KRW, Up 102% Year-on-Year

LNKBioMed announced on the 16th that it recorded sales of 9.1 billion KRW, operating profit of 1.7 billion KRW, and net profit of 1.8 billion KRW on a consolidated basis for the first quarter of this year.

Compared to the same period last year, sales increased by 18% and operating profit by 102%. This is the highest quarterly performance since LNKBioMed was listed on the KOSDAQ market in 2016.

A company representative explained, "The long-standing litigation issue was resolved through settlement, eliminating litigation-related costs, and the increased recognition of the PassLock-TM product in the U.S. along with aggressive marketing efforts have driven the performance."

LNKBioMed has achieved 1,800 PassLock-TM surgeries this month. This is three times faster than the time taken to reach 500 surgeries.